The tool allows an individualised estimation of lifetime breast cancer risk in the carriers and non-carriers of variants in BRCA1, BRCA2, PALB2, CHEK2, ATM, RAD51C, RAD51D, and BRIP1, and considers these modifiers of disease which may inform risk management. This evidence concerns the gene CHEK2 and breast cancer.